Fate Therapeutics, Inc. (FATE) has a consensus analyst rating of Buy, based on 31 analysts covering the stock. Of those, 16 recommend buying, 13 recommend holding, and 2 recommend selling.
The analyst consensus price target for FATE is $39.50, representing a +2,847.8% upside from the current price of $1.34. Price targets range from a low of $3.00 to a high of $145.00.
